These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 25354760)
21. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment. Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846 [TBL] [Abstract][Full Text] [Related]
22. Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a preliminary report. Karanasos A; Muramatsu T; Diletti R; Nauta S; Onuma Y; Lenzen M; Nakatani S; Van Mieghem NM; Schultz C; De Jaegere PP; Serruys PW; Zijlstra F; Regar E; van Geuns RJ Hellenic J Cardiol; 2015; 56(2):125-35. PubMed ID: 25854441 [TBL] [Abstract][Full Text] [Related]
23. Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot study. Vaquerizo B; Barros A; Pujadas S; Bajo E; Estrada D; Miranda-Guardiola F; Rigla J; Jiménez M; Cinca J; Serra A EuroIntervention; 2015 Sep; 11(5):555-63. PubMed ID: 25499833 [TBL] [Abstract][Full Text] [Related]
24. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials. Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ; JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650 [TBL] [Abstract][Full Text] [Related]
25. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303 [TBL] [Abstract][Full Text] [Related]
26. Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions. Fam JM; Ojeda S; Garbo R; Latib A; La Manna A; Vaquerizo B; Boukhris M; Vlachojannis GJ; van Geuns RJ; Ezhumalai B; Kawamoto H; van der Sijde J; Felix C; Pan M; Serdoz R; Boccuzzi GG; De Paolis M; Sardella G; Mancone M; Tamburino C; Smits PC; Di Mario C; Seth A; Serra A; Colombo A; Serruys P; Galassi AR; Zijlstra F; Van Mieghem NM; Diletti R EuroIntervention; 2017 Jun; 13(3):355-363. PubMed ID: 28218604 [TBL] [Abstract][Full Text] [Related]
27. Everolimus-eluting Bioresorbable Vascular Scaffold Implantation in Real World and Complex Coronary Disease: Procedural and 30-day Outcomes at Two Australian Centres. Robaei D; Back LM; Ooi SY; Pitney MR; Jepson N Heart Lung Circ; 2015 Sep; 24(9):854-9. PubMed ID: 25778622 [TBL] [Abstract][Full Text] [Related]
28. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Kočka V; Malý M; Toušek P; Buděšínský T; Lisa L; Prodanov P; Jarkovský J; Widimský P Eur Heart J; 2014 Mar; 35(12):787-94. PubMed ID: 24419808 [TBL] [Abstract][Full Text] [Related]
29. Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI. Yew KL Int J Cardiol; 2015; 186():74-6. PubMed ID: 25814348 [No Abstract] [Full Text] [Related]
30. Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry. Latini RA; Granata F; Ielasi A; Varricchio A; Moscarella E; Tespili M; Cortese B Catheter Cardiovasc Interv; 2016 Sep; 88(3):380-7. PubMed ID: 27038332 [TBL] [Abstract][Full Text] [Related]
32. Drug-eluting versus bare-metal stents in large coronary arteries of patients with ST-segment elevation myocardial infarction: findings from the ICAS registry. Abe D; Sato A; Hoshi T; Maruta S; Misaki M; Kakefuda Y; Watabe H; Hiraya D; Sakai S; Kawabe M; Takeyasu N; Aonuma K J Cardiol; 2014 Nov; 64(5):377-83. PubMed ID: 24685689 [TBL] [Abstract][Full Text] [Related]
33. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention. Allahwala UK; Cockburn JA; Shaw E; Figtree GA; Hansen PS; Bhindi R EuroIntervention; 2015 Feb; 10(10):1154-9. PubMed ID: 24647105 [TBL] [Abstract][Full Text] [Related]
34. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. Wöhrle J; Naber C; Schmitz T; Schwencke C; Frey N; Butter C; Brachmann J; Ingwersen M; Drabik A; Markovic S; Mathey DG EuroIntervention; 2015 Jun; 11(2):149-56. PubMed ID: 25499836 [TBL] [Abstract][Full Text] [Related]
35. Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers. Robaei D; Back L; Ooi SY; Pitney M; Jepson N J Invasive Cardiol; 2016 Aug; 28(8):316-22. PubMed ID: 26567454 [TBL] [Abstract][Full Text] [Related]
36. A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. Jamshidi P; Nyffenegger T; Sabti Z; Buset E; Toggweiler S; Kobza R; Cuculi F EuroIntervention; 2016 Apr; 11(13):1479-86. PubMed ID: 27107313 [TBL] [Abstract][Full Text] [Related]
37. One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS). Testa L; De Carlo M; Petrolini A; Rapetto C; Varbella F; Cortese B; Gabrielli G; Geraci S; Loi B; Boccuzzi G; Tarantini G; Fischetti D; Calabria P; Tomai F; Ribichini F; Tamburino C; Indolfi C; Bartorelli AL; Petronio AS; Bedogni F EuroIntervention; 2017 Jul; 13(4):424-431. PubMed ID: 28504219 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R). Nef H; Wiebe J; Achenbach S; Münzel T; Naber C; Richardt G; Mehilli J; Wöhrle J; Neumann T; Biermann J; Zahn R; Kastner J; Schmermund A; Pfannebecker T; Schneider S; Limbourg T; Hamm CW Cardiovasc Revasc Med; 2016; 17(1):34-7. PubMed ID: 26431767 [TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update. Toušek P; Kočka V; Malý M; Kozel M; Petr R; Hajsl M; Jarkovský J; Lisa L; Buděšínský T; Widimský P EuroIntervention; 2016 May; 12(1):23-9. PubMed ID: 27173858 [TBL] [Abstract][Full Text] [Related]
40. Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: results from a multicenter Italian experience. Moscarella E; Varricchio A; Stabile E; Latib A; Ielasi A; Tespili M; Cortese B; Calabrò P; Granata F; Panoulas VF; Franzone A; Trimarco B; Bonzani G; Esposito G; Colombo A Int J Cardiol; 2015 Nov; 199():366-72. PubMed ID: 26241643 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]